Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluoglu AM, Stewart ID, Wheeler E, Pietzner M, Gribble F, et al
Clinical trial participation provides free access to pharmaceutical-grade retatrutide with full medical supervision
In SURPASS 4 The risk of suffering from any major adverse cardiovascular event MACE-4 and MACE-3 (including myocardial infarction, stroke, hospitalization for angina, and all-cause death) with the highest dose of tirzepatide (15 mg per week) has been estimated at 050 (026095), which was intended to provide initial proof of the cardiovascular safety of tirzepatide [2, 5]
Researchers who prefer simplicity can use 10mg vials with 1mL reconstitution throughout the first 8-12 weeks (covering doses from 2mg through 8mg within a single draw), then switch to 20mg vials with 1mL reconstitution for the 8mg and 12mg maintenance phases
An updated systematic review and network meta-analysis of GLP-1 receptor agonists and polyagonists ranked retatrutide at or near the top for weight loss among the modern agents, while also flagging that the strongest-effect agents tend to carry the highest adverse-event burden
